利用转化信息学方法开展药代动力学药物相互作用的药物警戒研究
本研究基于FDA和Flockhart表中的CYP底物与抑制剂构建药代动力学药物相互作用对,利用FAERS 2004至2018年不良事件报告,采用收缩观测值与期望值比(Ω)分析筛选DDI与ADE关联。共识别149种CYP底物和62种CYP抑制剂,发现590种ADE与2085个PK DDI对及38种底物相关,并为紫杉醇-氯吡格雷与外周神经病变的关联找到了临床和实验证据。
要点
- 基于FAERS和CYP底物/抑制剂列表可系统筛选PK DDI相关不良事件。
- Ω>0且至少两种抑制剂配对的底物才纳入DDI-ADE关联分析。
- 紫杉醇-氯吡格雷与外周神经病变的关联有临床和实验证据支持。
核心结论
- 转化信息学方法可利用FAERS发现潜在的CYP相关底物-抑制剂与ADE关联。
研究设计与样本
- 基于FDA推荐和Drug Interactions Flockhart表的CYP底物与抑制剂构建PK DDI对,使用FAERS 2004至2018年ADE报告进行药物警戒分析。
主要发现
- 从FDA和Flockhart表识别出149种CYP底物和62种CYP抑制剂。
- 590种ADE与2085个PK DDI对及38种个体底物相关,ADE在不同CYP底物间存在重叠。
- 发现紫杉醇-氯吡格雷相互作用与外周神经病变关联的临床和实验证据。
关键数值与推荐
- 仅当CYP底物与至少两种抑制剂配对且Ω>0时才考虑DDI-ADE关联。
临床怎么用
- 临床药师可参考CYP底物-抑制剂配对和Ω阈值思路,利用FAERS信号支持PK DDI相关ADE的识别与评估。
局限性
- 研究结果为信号发现性质,需未来临床、人群和实验研究确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: While the pharmacokinetic (PK) mechanisms for many drug interactions (DDIs) have been established, pharmacovigilance studies related to these PK DDIs are limited. Using a large surveillance database, a translational informatics approach can systematically screen adverse drug events (ADEs) for many DDIs with known PK mechanisms. METHODS: We collected a set of substrates and inhibitors related to the cytochrome P450 (CYP) isoforms, as recommended by the United States Food and Drug Administration (FDA) and Drug Interactions Flockhart table™. The FDA's Adverse Events Reporting System (FAERS) was used to obtain ADE reports from 2004 to 2018. The substrate and inhibitor information were used to form PK DDI pairs for each of the CYP isoforms and Medical Dictionary for Regulatory Activities (MedDRA) preferred terms used for ADEs in FAERS. A shrinkage observed-to-expected ratio (Ω) analysis was performed to screen for potential PK DDI and ADE associations. RESULTS: We identified 149 CYP substrates and 62 CYP inhibitors from the FDA and Flockhart tables. Using FAERS data, only those DDI-ADE associations were considered that met the disproportionality threshold of Ω > 0 for a CYP substrate when paired with at least two inhibitors. In total, 590 ADEs were associated with 2085 PK DDI pairs and 38 individual substrates, with ADEs overlapping across different CYP substrates. More importantly, we were able to find clinical and experimental evidence for the paclitaxel-clopidogrel interaction associated with peripheral neuropathy in our study. CONCLUSION: In this study, we utilized a translational informatics approach to discover potentially novel CYP-related substrate-inhibitor and ADE associations using FAERS. Future clinical, population-based and experimental studies are needed to confirm our findings.
引用
- Wang L, Shendre A, Chiang CW, et al. A pharmacovigilance study of pharmacokinetic drug interactions using a translational informatics discovery approach. Br J Clin Pharmacol. 2021. PMID: 33543792. doi:10.1111/bcp.14762
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。